Share：
Share this content in WeChat
X
[Chinese][PDF]6951
• Clinical Article •
Prediction of HER-2 expression in breast cancer patients based on DCE-MRI intratumor and peritumoral imaging combined with TIC typing and Ki-67
ZHANG Chengmeng  DING Zhimin  CHEN Peng  LIU Qifeng  REN Chao 

Cite this article as: ZHANG C M, DING Z M, CHEN P, et al. Prediction of HER-2 expression in breast cancer patients based on DCE-MRI intratumor and peritumoral imaging combined with TIC typing and Ki-67[J]. Chin J Magn Reson Imaging, 2023, 14(4): 68-75. DOI:10.12015/issn.1674-8034.2023.04.012.


[Abstract] Objective To investigate the value of dynamic contrast enhancement MRI (DCE-MRI) based intratumoral and peritumoral radiomics models in combination with clinical and imaging indicators to predict the expression status of human epidermal growth factor receptor 2 (HER-2) in breast cancer patients.Materials and Methods A total of 272 patients' information with pathologically confirmed breast cancer from June 2018 to September 2022 were retrospectively collected, including 139 patients with positive HER-2 and 133 patients with negative HER-2. All cases underwent DCE-MRI examination before treatment. All 272 patients were divided into training set and validation set with a ratio of 7:3 by complete randomization method. In the training set Pearson correlation coefficients, recursive feature elimination and logistic regression were used to perform dimensionality reduction and model construction of intratumoral and peritumoral radiomics data. Multivariate logistic regression was used to screen the independent risk factors in clinical and imaging data, so as to construct the clinical model. Finally, the combined model was constructed by using intratumoral, peritumoral and clinical features. Area under the curve (AUC) was used to evaluate the efficacy of the model, and decision curve analysis (DCA) was used to evaluate the clinical value of the model.Results The AUC of clinical model, intratumoral model, peritumoral model, intratumoral + peritumoral model and combined model in the training set were 0.736, 0.784, 0.806, 0.831, 0.854, and the accuracy was 69.5%, 70.5%, 75.8%, 73.7%, 76.8%, respectively. The sensitivity was 87.6%, 53.6%, 71.1%, 62.9%, 72.2%, and the specificity was 50.5%, 88.2%, 80.6%, 84.9%, 81.7%, respectively. In the verification set, the AUC was 0.731, 0.724, 0.713, 0.780, 0.799, the accuracy was 73.2%, 70.7%, 68.3%, 73.1%, 78.0%, and the sensitivity was 76.2%, 61.9%, 88.1%, 76.2%, 78.6%, respectively. The specificity was 70.0%, 80.0%, 47.5%, 70.0% and 77.5%, respectively. By DeLong's test, in the training set there were statistically significant differences between combined model and the clinical model, the intratumoral model and the peritumoral model (Z=3.660, 2.791, 2.201, P=0.0003, 0.005, 0.028). There was no significant difference between the combined model and the intratumoral + peritumoral model (Z=1.583, P=0.114). The results showed that the combined model in the training set and validation set was better than the clinical model, intratumoral model, peritumoral model and intratumoral + peritumoral model in predicting the status of HER-2. DCA showed that the combined model had higher clinical utility than the clinical model, intratumoral model, peritumoral model and intratumoral + peritumoral model at risk thresholds of 13%-60% in the training set.Conclusions The combined model based on DCE-MRI intratumoral and peritumoral radiomics combined with clinical and imaging features can better predict the expression status of HER-2 in breast cancer patients.
[Keywords] radiomics；time-signal intensity curve；human epidermal growth factor receptor 2；predictive model；breast cancer；magnetic resonance imaging

ZHANG Chengmeng   DING Zhimin*   CHEN Peng   LIU Qifeng   REN Chao  

Department of Radiology, Yijishan Hospital of Wannan Medical College, Wuhu 241001, China

Corresponding author: Ding ZM, E-mail: dzmdoctor@139.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Medical Emollient Research Project of Red Cross Foundation of China (No. XM_HR_YXFN_2021_05_24); Health Research Project of Anhui Province (No. AHWJ2022b044).
Received  2022-11-20
Accepted  2023-04-11
DOI: 10.12015/issn.1674-8034.2023.04.012
Cite this article as: ZHANG C M, DING Z M, CHEN P, et al. Prediction of HER-2 expression in breast cancer patients based on DCE-MRI intratumor and peritumoral imaging combined with TIC typing and Ki-67[J]. Chin J Magn Reson Imaging, 2023, 14(4): 68-75. DOI:10.12015/issn.1674-8034.2023.04.012.

[1]
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]
ELSHAZLY A M, GEWIRTZ D A. An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer[J]. Cancer Drug Resist, 2022, 5(2): 472-486. DOI: 10.20517/cdr.2022.09.
[3]
ZHANG H, REN G P, WANG X L, et al. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases[J]. Breast Cancer Res Treat, 2012, 134(2): 743-749. DOI: 10.1007/s10549-012-2101-x.
[4]
LIAN Z W, WANG X, WU Q Y, et al. Study on the influence of delayed diagnosis on the diagnosis stage of HER2 positive breast cancer patients[J]. Chin J Cancer Prev Treat, 2023, 30(1): 43-47. DOI: 10.16073/j.cnki.cjcpt.2023.01.07.
[5]
EUN N L, KANG D, SON E J, et al. Texture analysis with 3.0-T MRI for association of response to neoadjuvant chemotherapy in breast cancer[J]. Radiology, 2020, 294(1): 31-41. DOI: 10.1148/radiol.2019182718.
[6]
EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials[J]. Lancet Oncol, 2021, 22(8): 1139-1150. DOI: 10.1016/S1470-2045(21)00288-6.
[7]
WAKS A G, WINER E P. Breast cancer treatment: a review[J]. JAMA, 2019, 321(3): 288-300. DOI: 10.1001/jama.2018.19323.
[8]
MARTÍNEZ-SÁEZ O, PRAT A. Current and future management of HER2-positive metastatic breast cancer[J]. JCO Oncol Pract, 2021, 17(10): 594-604. DOI: 10.1200/OP.21.00172.
[9]
GUCALP A, TRAINA T A. Targeting the androgen receptor in triple-negative breast cancer[J]. Curr Probl Cancer, 2016, 40(2/3/4): 141-150. DOI: 10.1016/j.currproblcancer.2016.09.004.
[10]
BRAMAN N, PRASANNA P, WHITNEY J, et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)-positive breast cancer[J/OL]. JAMA Netw Open, 2019, 2(4): e192561 [2022-11-01]. https://pubmed.ncbi.nlm.nih.gov/31002322. DOI: 10.1001/jamanetworkopen.2019.2561.
[11]
SHUAI G, YU Y X, DONG J, et al. The value of mammography based radiomics signature for preoperative prediction of HER2 expression in breast carcinoma[J]. Radiol Pract, 2022, 37(1): 41-47. DOI: 10.13609/j.cnki.1000-0313.2022.01.008.
[12]
YAN L P, LI J Y, TIAN L L, et al. Preliminary study on the application value of artificial intelligence breast ultrasound in primary breast cancer screening[J]. Mod Prev Med, 2023, 50(3): 567-570, 576. DOI: 10.20043/j.cnki.MPM.202203238.
[13]
CAO C L, LI J, CAO Y W, et al. Relationship between conventional ultrasound characteristics and shear wave elastic parameters and their molecular subtypes in patients with breast cancer[J]. Chin J Med Imaging, 2021, 29(8): 801-806. DOI: 10.3969/j.issn.1005-5185.2021.08.010. DOI: 10.3969/j.issn.1005-5185.2021.08.010.
[14]
ONISHI N, SADINSKI M, HUGHES M C, et al. Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer[J/OL]. Breast Cancer Res, 2020, 22(1): 58 [2022-11-01]. https://pubmed.ncbi.nlm.nih.gov/32466799. DOI: 10.1186/s13058-020-01292-9.
[15]
VAN GRIETHUYSEN J J M, FEDOROV A, PARMAR C, et al. Computational radiomics system to decode the radiographic phenotype[J/OL]. Cancer Res, 2017, 77(21): e104-e107 [2022-11-01]. https://pubmed.ncbi.nlm.nih.gov/29092951. DOI: 10.1158/0008-5472.CAN-17-0339.
[16]
KUHL C K, TRUHN D. The long route to standardized radiomics: unraveling the knot from the end[J]. Radiology, 2020, 295(2): 339-341. DOI: 10.1148/radiol.2020200059.
[17]
RIZZO S, BOTTA F, RAIMONDI S, et al. Radiomics: the facts and the challenges of image analysis[J/OL]. Eur Radiol Exp, 2018, 2(1): 36 [2022-11-01]. https://pubmed.ncbi.nlm.nih.gov/30426318. DOI: 10.1186/s41747-018-0068-z.
[18]
AVANZO M, STANCANELLO J, NAQA I EL. Beyond imaging: the promise of radiomics[J]. Phys Med, 2017, 38: 122-139. DOI: 10.1016/j.ejmp.2017.05.071.
[19]
LI Y R, QIN Q, ZHANG Y M, et al. Noninvasive determination of the IDH status of gliomas using MRI and MRI-based radiomics: impact on diagnosis and prognosis[J]. Curr Oncol, 2022, 29(10): 6893-6907. DOI: 10.3390/curroncol29100542.
[20]
YAMAZAKI M, YAGI T, TOMINAGA M, et al. Role of intratumoral and peritumoral CT radiomics for the prediction of EGFR gene mutation in primary lung cancer[J/OL]. Br J Radiol, 2022, 95(1140): 20220374 [2022-11-01]. https://pubmed.ncbi.nlm.nih.gov/36115683. DOI: 10.1259/bjr.20220374.
[21]
LÜ S N, ZHANG Y W, SONG J W, et al. Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway[J/OL]. Med Oncol, 2023, 40(1): 5 [2022-11-01]. https://pubmed.ncbi.nlm.nih.gov/36308575. DOI: 10.1007/s12032-022-01872-z.
[22]
SHARAF B M, GIDDEY A D, AL-HROUB H M, et al. Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab[J]. Cancer Chemother Pharmacol, 2022, 90(6): 467-488. DOI: 10.1007/s00280-022-04478-4.
[23]
GUARNERI V, BRAS-MARISTANY F, DIECI M V, et al. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: a correlative analysis from the PerELISA trial[J/OL]. EBioMedicine, 2022, 85: 104320 [2022-11-01]. https://pubmed.ncbi.nlm.nih.gov/36374768. DOI: 10.1016/j.ebiom.2022.104320.
[24]
DUNTON K, VONDELING G, HANCOCK E, et al. Methods for estimating long-term outcomes for trastuzumab deruxtecan in HER2-positive unresectable or metastatic breast cancer after two or more anti-HER2 therapies[J]. Target Oncol, 2022, 17(6): 655-663. DOI: 10.1007/s11523-022-00923-9.
[25]
MA X P, LI Y, LI L, et al. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases[J]. Ann Med, 2022, 54(1): 3085-3095. DOI: 10.1080/07853890.2022.2139411.
[26]
SMITH I, PROCTER M, GELBER R D, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial[J]. Lancet, 2007, 369(9555): 29-36. DOI: 10.1016/S0140-6736(07)60028-2.
[27]
FENG H X, GU L, AN L H, et al. Prediction of the expression of HER-2 in breast cancer based on intravoxel incoherent motion and dynamic contrast enhanced magnetic resonance imaging[J]. J Clin Radiol, 2022, 41(8): 1432-1437. DOI: 10.13437/j.cnki.jcr.2022.08.005.
[28]
ZHANG J, ZOU Z Q, ZHAN D, et al. Analysis of the differential dalue of diffusion-weighted imaging in differentiating HER-2 low expression from HER-2-positive breast cancer[J]. Chin J CT MRI, 2022, 20(12): 86-88. DOI: 10.3969/j.issn.1672-5131.2022.12.034.
[29]
MONTICCIOLO D L, NEWELL M S, MOY L, et al. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR[J]. J Am Coll Radiol, 2018, 15(3Pt A): 408-414. DOI: 10.1016/j.jacr.2017.11.034.
[30]
ROTILI A, TRIMBOLI R M, PENCO S, et al. Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection[J]. Breast Cancer Res Treat, 2020, 180(1): 111-120. DOI: 10.1007/s10549-019-05519-y.
[31]
KIM J Y, KIM J J, HWANGBO L, et al. Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk[J]. Eur Radiol, 2020, 30(1): 66-76. DOI: 10.1007/s00330-019-06383-6.
[32]
ZHANG H, SHAN C H, WANG Y. The value of dynamic contrast enhancement and diffusion weighted imaging in diagnosis and prediction of breast cancer recurrence[J]. Chin J Magn Reson Imaging, 2017, 8(11): 827-833. DOI: 10.12015/issn.1674-8034.2017.11.006.
[33]
LI F F, CHEN H Y, WANG L P. Diffusion weighted imaging and dynamic contrast-enhanced MR imaging features of her-2 over expression subtype of breast cancer[J]. China Med Devices, 2016, 31(10): 51-54, 61. DOI: 10.3969/j.issn.1674-1633.2016.10.015.
[34]
PICKLES M D, LOWRY M, MANTON D J, et al. Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators[J]. Eur Radiol, 2015, 25(4): 1097-1106. DOI: 10.1007/s00330-014-3502-5.
[35]
XIE T W, WANG Z, ZHAO Q F, et al. Machine learning-based analysis of MR multiparametric radiomics for the subtype classification of breast cancer[J/OL]. Front Oncol, 2019, 9: 505 [2022-11-01]. https://pubmed.ncbi.nlm.nih.gov/31259153. DOI: 10.3389/fonc.2019.00505.
[36]
LEITHNER D, HORVAT J V, MARINO M A, et al. Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results[J/OL]. Breast Cancer Res, 2019, 21(1): 106 [2022-11-02]. https://pubmed.ncbi.nlm.nih.gov/31514736. DOI: 10.1186/s13058-019-1187-z.
[37]
YU H W, MENG X Q, CHEN H, et al. Correlation between mammographic radiomics features and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer[J/OL]. Front Oncol, 2020, 10: 41 2 [2022-11-02]. https://pubmed.ncbi.nlm.nih.gov/32351879. DOI: 10.3389/fonc.2020.00412.
[38]
BRAMAN N M, ETESAMI M, PRASANNA P, et al. Erratum to: Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI[J/OL]. Breast Cancer Res, 2017, 19(1): 80 [2022-11-04]. https://pubmed.ncbi.nlm.nih.gov/28521821. DOI: 10.1186/s13058-017-0862-1.
[39]
HWANG K T, KIM Y A, KIM J, et al. The influences of peritumoral lymphatic invasion and vascular invasion on the survival and recurrence according to the molecular subtypes of breast cancer[J]. Breast Cancer Res Treat, 2017, 163(1): 71-82. DOI: 10.1007/s10549-017-4153-4.
[40]
WU J, LI B L, SUN X L, et al. Heterogeneous enhancement patterns of tumor-adjacent parenchyma at MR imaging are associated with dysregulated signaling pathways and poor survival in breast cancer[J]. Radiology, 2017, 285(2): 401-413. DOI: 10.1148/radiol.2017162823.
[41]
JIANG Y, CHENG Y J, GUO L, et al. A feasibility study of classification between breast carcinoma in situ and invasive carcinoma using intratumoral and peritumoral radiomics based on dynamic contrast-enhanced MRI[J]. Chin J Radiol, 2022, 56(9): 976-981. DOI: 10.3760/cma.j.cn112149-20211222-01130. DOI: 10.3760/cma.j.cn112149-20211222-01130.
[42]
ZHU Y Q, JI H, ZHU Y F, et al. Predictive value of preoperative MRI-based nomogram for axillary lymph node metastasis in breast cancer[J]. Chin J Magn Reson Imaging, 2022, 13(5): 52-58. DOI: 10.12015/issn.1674-8034.2022.05.010. DOI: 10.12015/issn.1674-8034.2022.05.010.
[43]
MAO N, DAI Y, LIN F, et al. Radiomics nomogram of DCE-MRI for the prediction of axillary lymph node metastasis in breast cancer[J/OL]. Front Oncol, 2020, 10: 541849 [2022-11-05]. https://pubmed.ncbi.nlm.nih.gov/33381444. DOI: 10.3389/fonc.2020.541849.
[44]
MING J, CHEN Y, LIU Y, et al. Value of preoperative prediction of Ki-67 expression in breast cancer based on DCE-MRI intratumoral combined with peritumoral radiomics model[J]. Chin J Magn Reson Imaging, 2022, 13(10): 132-137, 149. DOI: 10.12015/issn.1674-8034.2022.10.020.
[45]
BOTTINI A, BERRUTI A, BERSIGA A, et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer[J]. Br J Cancer, 2001, 85(8): 1106-1112. DOI: 10.1054/bjoc.2001.2048.
[46]
YU W. Ki-67 expression in T1 primary breast cancer tissue and its relationship with Her-2 and ER[J]. Int J Surg, 2011, 38(8)529-531. DOI: 10.3760/cma.j.issn.1673-4203.2011.08.007
[47]
TANG W J, LI K, WANG H Y, et al. Study of enhancing pattern and correlationship with tumor microvessel density in breast tumors with dynamic MRI[J]. Chin J Med Comput Imaging, 2004, 10(1): 23-28. DOI: 10.19627/j.cnki.cn31-1700/th.2004.01.006.
[48]
HAO L, YU R S, CUI F, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of mr imaging features[J]. Natl Med J China, 2013, 93(11): 819-823. DOI: 10.3760/cma.j.issn.0376-2491.2013.11.007.

PREV Predictive value of DCE-MRI features of breast cancer on hormone receptor, HER-2 and triple negative breast cancer
NEXT Value of edema on T2WI before treatment in predicting the efficacy of neoadjuvant chemotherapy for breast cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn